Categories
Publication

NanOlogy Fact Sheet (Jan 2020)

In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to therapeutic levels of taxanes for several weeks, causes a sustained tumoricidal response, produces clinical benefits without local or systemic toxicity, and may facilitate treatment of metastatic disease.

Leave a Reply

Your email address will not be published. Required fields are marked *